JP2010537988A - 紅斑を治療するための改良ブリモニジン組成物 - Google Patents

紅斑を治療するための改良ブリモニジン組成物 Download PDF

Info

Publication number
JP2010537988A
JP2010537988A JP2010522973A JP2010522973A JP2010537988A JP 2010537988 A JP2010537988 A JP 2010537988A JP 2010522973 A JP2010522973 A JP 2010522973A JP 2010522973 A JP2010522973 A JP 2010522973A JP 2010537988 A JP2010537988 A JP 2010537988A
Authority
JP
Japan
Prior art keywords
composition
composition according
gel
agent
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2010522973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010537988A5 (cg-RX-API-DMAC7.html
Inventor
クラウス テオバルト
クリストファー ヴィー ポワラ
Original Assignee
ガルデマ ラボラトリーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガルデマ ラボラトリーズ インコーポレイテッド filed Critical ガルデマ ラボラトリーズ インコーポレイテッド
Publication of JP2010537988A publication Critical patent/JP2010537988A/ja
Publication of JP2010537988A5 publication Critical patent/JP2010537988A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010522973A 2007-08-31 2008-08-29 紅斑を治療するための改良ブリモニジン組成物 Abandoned JP2010537988A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96719107P 2007-08-31 2007-08-31
PCT/US2008/010290 WO2009032223A1 (en) 2007-08-31 2008-08-29 Improved brimonidine compositions for treating erythema

Publications (2)

Publication Number Publication Date
JP2010537988A true JP2010537988A (ja) 2010-12-09
JP2010537988A5 JP2010537988A5 (cg-RX-API-DMAC7.html) 2011-10-13

Family

ID=40407909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522973A Abandoned JP2010537988A (ja) 2007-08-31 2008-08-29 紅斑を治療するための改良ブリモニジン組成物

Country Status (12)

Country Link
US (3) US20090061020A1 (cg-RX-API-DMAC7.html)
EP (1) EP2200617A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010537988A (cg-RX-API-DMAC7.html)
KR (1) KR20100055453A (cg-RX-API-DMAC7.html)
CN (2) CN101808645A (cg-RX-API-DMAC7.html)
AR (1) AR068816A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008296948A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816097A2 (cg-RX-API-DMAC7.html)
CA (1) CA2698680A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010002392A (cg-RX-API-DMAC7.html)
NO (1) NO20100301L (cg-RX-API-DMAC7.html)
WO (1) WO2009032223A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533271A (ja) * 2011-11-10 2014-12-11 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物
US10201535B2 (en) 2011-11-10 2019-02-12 Allergan, Inc. Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
KR101453601B1 (ko) * 2009-05-29 2014-10-22 갈데르마 리써어치 앤드 디벨로프먼트 주입으로 인한 피부 반응 감소를 위한 필러와 아드레날린 수용체 작용제의 주사가능한 조합
US20110224216A1 (en) * 2009-10-26 2011-09-15 Galderma Laboratories Inc. Methods of Treating or Preventing Acute Erythema
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
AU2011231543B2 (en) * 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
CA2792649A1 (en) 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
JP2013540142A (ja) * 2010-10-21 2013-10-31 ガルデルマ・ソシエテ・アノニム 局所ゲル組成物
EP2444068B2 (en) 2010-10-21 2017-12-06 Galderma S.A. Brimonidine gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
CN107007546A (zh) 2011-02-15 2017-08-04 阿勒根公司 用于治疗红斑痤疮的症状的羟甲唑啉药物乳膏组合物
RU2014119879A (ru) 2011-10-19 2015-11-27 Галдерма С.А. Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
WO2015191917A1 (en) 2014-06-11 2015-12-17 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
WO2019014518A1 (en) * 2017-07-14 2019-01-17 Galderma Research And Development METHODS AND COMPOSITIONS FOR REDUCING ADVERSE EFFECTS OF CHEMOTHERAPEUTIC TREATMENTS
CN113784712A (zh) 2019-05-01 2021-12-10 克雷西奥生物科技有限公司 治疗瘙痒的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
GB8827968D0 (en) * 1988-11-30 1989-01-05 Boots Co Plc Sunscreen compositions
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050276765A1 (en) * 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
US20110224215A1 (en) * 2007-12-21 2011-09-15 Galderma Laboratories, Inc. Pre-surgical treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533271A (ja) * 2011-11-10 2014-12-11 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物
US10201535B2 (en) 2011-11-10 2019-02-12 Allergan, Inc. Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Also Published As

Publication number Publication date
CN101808645A (zh) 2010-08-18
WO2009032223A1 (en) 2009-03-12
US20120282346A1 (en) 2012-11-08
CN102552112A (zh) 2012-07-11
KR20100055453A (ko) 2010-05-26
MX2010002392A (es) 2010-07-28
AR068816A1 (es) 2009-12-09
US20090061020A1 (en) 2009-03-05
EP2200617A4 (en) 2011-01-12
BRPI0816097A2 (pt) 2016-11-01
CA2698680A1 (en) 2009-03-12
EP2200617A1 (en) 2010-06-30
US20120040016A1 (en) 2012-02-16
NO20100301L (no) 2010-03-25
AU2008296948A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
JP2010537988A (ja) 紅斑を治療するための改良ブリモニジン組成物
ES2424644T3 (es) Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
ES2376172T5 (es) Compuestos, formulaciones y métodos para tratar o prevenir la rosácea
RU2538729C2 (ru) Применение агонистов альфа 2 адренергических рецепторов для лечения или предотвращения псориаза
JP5580210B2 (ja) 手術前治療
JP2010537988A5 (cg-RX-API-DMAC7.html)
DK2552449T3 (en) COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
US11382900B2 (en) Composition for preventing or treating sleep disorders
US20200197379A1 (en) Composition for preventing or treating atopic dermatitis
KR20140091543A (ko) 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법
KR20140091544A (ko) 모세혈관종 치료방법
US20080255238A1 (en) Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
US20230321059A1 (en) Mepyramine for use in the topical treatment of neuropathic pain
HK1175698B (en) Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis
HK1180208B (en) Compositions comprising brimonidine for the treatment of erythema
HK1180208A (en) Compositions comprising brimonidine for the treatment of erythema
HK1204996B (en) Compounds, formulations, and methods for treating or preventing rosacea

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110826

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20130430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130501